References
- National Collaborating Centre for Women's and Children's Health. Long-acting reversible contraception: The effective and appropriate use of long-acting reversible contraception. Royal College of Obstetricians and Gynaecologists (RCOG), LondonUK 2005, Available at http://www.nice.org.uk/Guidance/CG30/Guidance/pdf/English
- National cost impact report. National Institute for Health and Clinical Excellence, London 2005, Available at http://www.nice.org.uk/Guidance/CG30/CostReport/pdf/English
- Trussell J. The cost of unintended pregnancy in the United States. Contraception 2007; 75: 168–170
- Ashraf T, Arnold S B, Maxfield M, Jr. Cost-effectiveness of levonorgestrel subdermal implants. Comparison with other contraceptive methods available in the United States. J Reprod Med 1994; 39: 791–798
- Ortmeier B G, Sauer K A, Langley P C, Bealmear B K. A cost-benefit analysis of four hormonal contraceptive methods. Clin Ther 1994; 16: 707–713
- Hughes D, McGuire A. The cost-effectiveness of family planning service provision. J Public Health Med 1996; 18: 189–196
- Phillips C J. Economic analysis of long-term reversible contraceptives. Focus on Implanon. Pharmacoeconomics 2000; 17: 209–221
- Varney S J, Guest J F. Relative cost effectiveness of Depo-Provera, Implanon, and Mirena in reversible long-term hormonal contraception in the UK. Pharmacoeconomics 2004; 22: 1141–1151
- Sonnenberg F A, Burkman R T, Hagerty C G, et al. Costs and net health effects of contraceptive methods. Contraception 2004; 69: 447–459
- Sonnenberg F A, Burkman R T, Speroff L, et al. Cost-effectiveness and contraceptive effectiveness of the transdermal contraceptive patch. Am J Obstet Gynecol 2005; 192: 1–9
- Mavranezouli I. The cost-effectiveness of long-acting reversible contraceptive methods in the UK: Analysis based on a decision-analytic model developed for a National Institute for Health and Clinical Excellence (NICE) clinical practice guideline. Human Reprod 2008; 23: 1338–1345